We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Getein Biotech, Inc.

Getein Biotech, Inc. is a fully integrated in vitro diagnostic company that develops, manufactures and distributes an... read more Featured Products: More products

Download Mobile App





Getein Biotech Presents Sustainable Lab Solutions with Unlimited Possibilities at AACC 2022

By LabMedica International staff writers
Posted on 26 Jul 2022

Getein Biotech, Inc. More...

(Nanjing, China) is presenting its sustainable diagnostic solutions that offer unlimited possibilities for laboratories at the 2022 AACC Clinical Lab Expo.

AT AACC 2022, Getein will exhibit its range of POCT immunofluorescence quantitative analyzers, including the Getein1160, Getein1180, Getein1200 and Getein1600. These immunofluorescence quantitative analyzers automate the detection and quantification of markers for cardiovascular diseases, renal diseases, inflammation, fertility, diabetes mellitus, bone metabolism, tumor, and thyroid in biological samples. Getein is also showcasing the MAGICL6000 chemiluminescence immunoassay analyzer that automates the detection and quantification of markers for thyroid disease, inflammation, cardiac diseases, fertility, diabetes mellitus, bone metabolism, tumor, infectious disease, anemia, and immune globulin by analyzing human serum, plasma, whole blood and urine samples.

In addition, Getein will exhibit the fully automated CM-400 clinical chemistry analyzer for the quantitative analysis of chemical components in human serum, plasma, whole blood, urine, and cerebrospinal liquid samples. CM-400 is characterized by open reagents, discrete system, emergency priority, random access and an external computer. The analyzer consists of the main instrument and the computer with the main instrument composed of an optical system, reaction system, sample adding system, reagent adding system, cleaning system and mixing system, with an optional electrolyte module.

Getein is also highlighting the BHA-3000 and BHA-5000 automatic hematology analyzers that provide quantitative analysis of a patient's blood components at high speed with accuracy, alongside the XN06 semi-automated blood coagulation analyzer for testing four routine clotting test items, namely PT, TT, APTT and FIB. Getein will demonstrate its One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) for the qualitative detection of SARS-CoV-2 antigens in human nasal swab samples. The test is suitable for medical laypersons as a self-test at home or at work. Getein provides a comprehensive range of COVID-19 testing solutions, including neutralizing antibody tests, antigen tests and IgM/IgG antibody tests. Getein also offers the Monkeypox Virus Real-time PCR Kit for the qualitative detection of MPV in serum or lesion exudate samples.
 

Related Links:
Getein Biotech, Inc. 


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.